Research Article
Peripheral Nerve Ultrasonography in Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Multifocal Motor Neuropathy: Correlations with Clinical and Neurophysiological Data
Table 4
Clinical, neurophysiological, and ultrasonographic data: upper limbs.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Results are reported as average ± standard deviation. CMAP: compound muscle action potential. CSA: cross-sectional area. CV: conduction velocity. SNAP: sensory action potential. INCAT (inflammatory neuropathy cause and treatment) upper limbs score: no/minimal impairment = 0-1; moderate impairment = 2; severe impairment = 3–5. Significant difference () versus “no/minimal impairment.” Significant difference () versus “severe impairment.” |